Alluvi, previously BI 4744, offers a promising breakthrough in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates compelling effectiveness in patient trials, https://alluvi-peptides499848.sunderwiki.com/user